{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T08:02:01Z","timestamp":1785225721866,"version":"3.55.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T00:00:00Z","timestamp":1706486400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T00:00:00Z","timestamp":1706486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P01 CA217797"],"award-info":[{"award-number":["P01 CA217797"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P01 CA217797"],"award-info":[{"award-number":["P01 CA217797"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001634","name":"Gateway for Cancer Research","doi-asserted-by":"publisher","award":["G-17-1500"],"award-info":[{"award-number":["G-17-1500"]}],"id":[{"id":"10.13039\/100001634","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s11060-024-04571-z","type":"journal-article","created":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T15:03:11Z","timestamp":1706540591000},"page":"493-501","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Iron-based biomarkers for personalizing pharmacological ascorbate therapy in glioblastoma: insights from a phase 2 clinical trial"],"prefix":"10.1007","volume":"166","author":[{"given":"M. S.","family":"Petronek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. L.","family":"Bodeker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Y.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Teferi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. L.","family":"Eschbacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. A.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. T.","family":"Loeffler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. J.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. M.","family":"Buatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V. A.","family":"Magnotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. G.","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,29]]},"reference":[{"key":"4571_CR1","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1056\/NEJMra0708126","volume":"359","author":"PY Wen","year":"2008","unstructured":"Wen PY, Kesari S (2008) Malignant gliomas in adults. N Engl J Med 359:492\u2013507","journal-title":"N Engl J Med"},{"key":"4571_CR2","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987\u2013996","journal-title":"N Engl J Med"},{"key":"4571_CR3","first-page":"iii1","volume":"23","author":"QT Ostrom","year":"2021","unstructured":"Ostrom QT, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS (2021) CBTRUS Statistical Report: primary brain and other Central Nervous System tumors diagnosed in the United States in 2014\u20132018. Neurooncology 23:iii1\u2013iii105","journal-title":"Neurooncology"},{"key":"4571_CR4","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.ccell.2015.09.002","volume":"28","author":"DL Schonberg","year":"2015","unstructured":"Schonberg DL et al (2015) Preferential Iron trafficking characterizes glioblastoma stem-like cells. Cancer Cell 28:441\u2013455","journal-title":"Cancer Cell"},{"key":"4571_CR5","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/0005-2728(96)00022-9","volume":"1275","author":"PM Harrison","year":"1996","unstructured":"Harrison PM, Arosio P (1996) The ferritins: molecular properties, iron storage function and cellular regulation. Biochim et Biophys Acta (BBA) - Bioenergetics 1275:161\u2013203","journal-title":"Biochim et Biophys Acta (BBA) - Bioenergetics"},{"key":"4571_CR6","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s41232-022-00240-8","volume":"42","author":"K Tabu","year":"2022","unstructured":"Tabu K, Taga T (2022) Cancer ego-system in glioma: an iron-replenishing niche network systemically self-organized by cancer stem cells. Inflamm Regeneration 42:54","journal-title":"Inflamm Regeneration"},{"key":"4571_CR7","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.ccell.2017.02.018","volume":"31","author":"JD Schoenfeld","year":"2017","unstructured":"Schoenfeld JD et al (2017) O2\u22c5\u2013 and H2O2-Mediated disruption of Fe Metabolism causes the Differential susceptibility of NSCLC and GBM Cancer cells to pharmacological ascorbate. Cancer Cell 31:487\u2013500e8","journal-title":"Cancer Cell"},{"key":"4571_CR8","doi-asserted-by":"publisher","first-page":"532","DOI":"10.2307\/3579271","volume":"145","author":"GR Buettner","year":"1996","unstructured":"Buettner GR, Jurkiewicz BA (1996) Catalytic metals, ascorbate and free radicals: combinations to avoid. Radiat Res 145:532\u2013541","journal-title":"Radiat Res"},{"key":"4571_CR9","doi-asserted-by":"crossref","unstructured":"Bielski BHJ (1982) Chemistry of ascorbic acid radicals. In: Ascorbic acid: chemistry, metabolism, and uses, vol 200. American Chemical Society, pp 81\u2013100","DOI":"10.1021\/ba-1982-0200.ch004"},{"key":"4571_CR10","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.redox.2017.09.012","volume":"14","author":"JD Schoenfeld","year":"2018","unstructured":"Schoenfeld JD et al (2018) Redox active metals and H2O2 mediate the increased efficacy of pharmacological ascorbate in combination with gemcitabine or radiation in pre-clinical sarcoma models. Redox Biol 14:417\u2013422","journal-title":"Redox Biol"},{"key":"4571_CR11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-3952","author":"MS Petronek","year":"2023","unstructured":"Petronek MS et al (2023) Magnetic resonance imaging of iron metabolism with T2* mapping predicts an enhanced clinical response to pharmacological ascorbate in patients with GBM. Clin Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-3952","journal-title":"Clin Cancer Res"},{"key":"4571_CR12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.18383\/j.tom.2015.00136","volume":"1","author":"C Liu","year":"2015","unstructured":"Liu C et al (2015) Quantitative susceptibility mapping: contrast mechanisms and clinical applications. Tomography 1:3\u201317","journal-title":"Tomography"},{"key":"4571_CR13","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1016\/j.neuroimage.2012.05.049","volume":"62","author":"C Langkammer","year":"2012","unstructured":"Langkammer C et al (2012) Quantitative susceptibility mapping (QSM) as a means to measure brain iron? A post mortem validation study. NeuroImage 62:1593\u20131599","journal-title":"NeuroImage"},{"key":"4571_CR14","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1016\/j.neuroimage.2011.08.077","volume":"59","author":"B Bilgic","year":"2012","unstructured":"Bilgic B, Pfefferbaum A, Rohlfing T, Sullivan EV, Adalsteinsson E (2012) MRI estimates of brain iron concentration in normal aging using quantitative susceptibility mapping. NeuroImage 59:2625\u20132635","journal-title":"NeuroImage"},{"key":"4571_CR15","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1007\/s00702-012-0905-9","volume":"119","author":"H Mochizuki","year":"2012","unstructured":"Mochizuki H, Yasuda T (2012) Iron accumulation in Parkinson\u2019s disease. J Neural Transm 119:1511\u20131514","journal-title":"J Neural Transm"},{"key":"4571_CR16","doi-asserted-by":"publisher","first-page":"6590","DOI":"10.1158\/1078-0432.CCR-19-0594","volume":"25","author":"BG Allen","year":"2019","unstructured":"Allen BG et al (2019) First-in-human phase I clinical trial of pharmacologic ascorbate combined with Radiation and Temozolomide for newly diagnosed Glioblastoma. Clin Cancer Res 25:6590\u20136597","journal-title":"Clin Cancer Res"},{"key":"4571_CR17","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.neuroimage.2015.02.041","volume":"111","author":"C Langkammer","year":"2015","unstructured":"Langkammer C et al (2015) Fast quantitative susceptibility mapping using 3D EPI and total generalized variation. NeuroImage 111:622\u2013630","journal-title":"NeuroImage"},{"key":"4571_CR18","doi-asserted-by":"publisher","first-page":"e0182954","DOI":"10.1371\/journal.pone.0182954","volume":"12","author":"AM Rosager","year":"2017","unstructured":"Rosager AM et al (2017) Transferrin receptor-1 and ferritin heavy and light chains in astrocytic brain tumors: expression and prognostic value. PLoS ONE 12:e0182954","journal-title":"PLoS ONE"},{"key":"4571_CR19","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/0092-8674(88)90098-0","volume":"53","author":"EW M\u00fcllner","year":"1988","unstructured":"M\u00fcllner EW, K\u00fchn LC (1988) A stem-loop in the 3\u2032 untranslated region mediates iron-dependent regulation of transferrin receptor mRNA stability in the cytoplasm. Cell 53:815\u2013825","journal-title":"Cell"},{"key":"4571_CR20","doi-asserted-by":"publisher","first-page":"6405","DOI":"10.1016\/S0021-9258(17)37386-6","volume":"269","author":"G Cairo","year":"1994","unstructured":"Cairo G, Pietrangelo A (1994) Transferrin receptor gene expression during rat liver regeneration. Evidence for post-transcriptional regulation by iron regulatory factorB, a second iron-responsive element-binding protein. J Biol Chem 269:6405\u20136409","journal-title":"J Biol Chem"},{"key":"4571_CR21","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.redox.2017.08.017","volume":"14","author":"KE Brandt","year":"2018","unstructured":"Brandt KE et al (2018) Augmentation of intracellular iron using iron sucrose enhances the toxicity of pharmacological ascorbate in colon cancer cells. Redox Biol 14:82\u201387","journal-title":"Redox Biol"},{"key":"4571_CR22","doi-asserted-by":"publisher","first-page":"102651","DOI":"10.1016\/j.redox.2023.102651","volume":"62","author":"MS Petronek","year":"2023","unstructured":"Petronek MS et al (2023) Magnetite nanoparticles as a kinetically favorable source of iron to enhance GBM response to chemoradiosensitization with pharmacological ascorbate. Redox Biol 62:102651","journal-title":"Redox Biol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-024-04571-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-024-04571-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-024-04571-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T12:49:58Z","timestamp":1708606198000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-024-04571-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,29]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["4571"],"URL":"https:\/\/doi.org\/10.1007\/s11060-024-04571-z","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,29]]},"assertion":[{"value":"8 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}